Advertisement
Canada markets closed

  • S&P/TSX

    21,554.86
    -26.49 (-0.12%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.57 (+0.04%)
     

  • CAD/USD

    0.7302
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    82.34
    +0.17 (+0.21%)
     

  • Bitcoin CAD

    88,040.76
    +519.38 (+0.59%)
     

  • CMC Crypto 200

    1,348.37
    -11.95 (-0.88%)
     

  • GOLD FUTURES

    2,334.70
    -34.30 (-1.45%)
     

  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • NASDAQ

    17,689.36
    -32.23 (-0.18%)
     

  • VOLATILITY

    13.20
    -0.08 (-0.60%)
     

  • FTSE

    8,237.72
    -34.74 (-0.42%)
     

  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Agenus Announces Virtual Annual Shareholders Meeting

Business Wire
·1 min read

LEXINGTON, Mass., June 04, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

ADVERTISEMENT

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com